title: FDA Approval of Desmopressin for Nocturia.
authors.affiliation: Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts2University of Toronto Clinician-Scientist Program, Toronto, Ontario, Canada.
authors.forename: Michael
authors.initials: M
authors.lastname: Fralick
authors.affiliation: Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
authors.forename: Aaron S
authors.initials: AS
authors.lastname: Kesselheim
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D026683:Advisory Committees; D002648:Child; D003894:Deamino Arginine Vasopressin / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced; D053158:Nocturia / Q000188:drug therapy* / Q000209:etiology; D011358:Product Surveillance, Postmarketing; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D003894:Deamino Arginine Vasopressin